Thoratec Collects LVAD Cost Data In Support Of Medicare Reimbursement
This article was originally published in The Gray Sheet
Executive Summary
Thoratec is confident its HeartMate VE left ventricular assist device will secure adequate reimbursement by Medicare despite its relatively high cost because it is associated with higher survival rates and quality of life scores than current medical alternatives
You may also be interested in...
Thoratec HeartMate VE LVAS Cuts Mortality Rate By 27% At One Year
A 52% one-year survival rate for patients implanted with the Thoratec HeartMate VE represents a 27% improvement over medical therapy for end-stage heart failure when the left ventricular assist system is used as an alternative to transplant
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.